Worthington Industries, Inc. (WOR) Forms $44.07 Double Bottom; Algorx Pharmaceuticals Has 1.71 Sentiment

Agile Therapeutics, Inc. (NASDAQ:AGRX) Logo

Algorx Pharmaceuticals Inc (AGRX) investors sentiment increased to 1.71 in 2017 Q4. It’s up 0.36, from 1.35 in 2017Q3. The ratio improved, as 29 hedge funds increased or started new equity positions, while 17 reduced and sold stock positions in Algorx Pharmaceuticals Inc. The hedge funds in our database reported: 22.48 million shares, down from 23.16 million shares in 2017Q3. Also, the number of hedge funds holding Algorx Pharmaceuticals Inc in top ten equity positions was flat from 4 to 4 for the same number . Sold All: 11 Reduced: 6 Increased: 16 New Position: 13.

Worthington Industries, Inc. (WOR) formed double bottom with $41.43 target or 6.00% below today’s $44.07 share price. Worthington Industries, Inc. (WOR) has $2.67 billion valuation. The stock decreased 0.70% or $0.31 during the last trading session, reaching $44.07. About 200,358 shares traded. Worthington Industries, Inc. (NYSE:WOR) has declined 16.89% since May 3, 2017 and is downtrending. It has underperformed by 28.44% the S&P500.

Agile Therapeutics, Inc., a forward-thinking women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. The company has market cap of $98.64 million. The Company’s lead product candidate is Twirla, also known as AG200-15, a once-weekly contraceptive patch, which completed Phase III clinical trials. It currently has negative earnings. The firm is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.

Analysts await Agile Therapeutics, Inc. (NASDAQ:AGRX) to report earnings on May, 14. They expect $-0.19 earnings per share, up 26.92% or $0.07 from last year’s $-0.26 per share. After $-0.18 actual earnings per share reported by Agile Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 5.56% negative EPS growth.

The stock decreased 1.37% or $0.04 during the last trading session, reaching $2.88. About 42,621 shares traded. Agile Therapeutics, Inc. (AGRX) has declined 11.00% since May 3, 2017 and is downtrending. It has underperformed by 22.55% the S&P500.

Proquest Associates Iv Llc holds 18.09% of its portfolio in Agile Therapeutics, Inc. for 5.06 million shares. Caxton Corp owns 1.82 million shares or 5.95% of their US portfolio. Moreover, Aisling Capital Llc has 0.69% invested in the company for 1.30 million shares. The Sweden-based Investor Ab has invested 0.62% in the stock. Perceptive Advisors Llc, a New York-based fund reported 3.38 million shares.

Since January 24, 2018, it had 1 insider buy, and 3 insider sales for $1.96 million activity. The insider LAMPRINAKOS JOHN G sold 7,500 shares worth $343,725. ENDRES MICHAEL J bought 3,000 shares worth $119,340. On Wednesday, April 4 LYTTLE CATHERINE M sold $1.40M worth of Worthington Industries, Inc. (NYSE:WOR) or 34,500 shares. BRINKMAN DALE T also sold $332,180 worth of Worthington Industries, Inc. (NYSE:WOR) on Wednesday, January 24.

Among 3 analysts covering Worthington Industries (NYSE:WOR), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Worthington Industries has $4700 highest and $30 lowest target. $40.50’s average target is -8.10% below currents $44.07 stock price. Worthington Industries had 14 analyst reports since August 27, 2015 according to SRatingsIntel. The firm has “Hold” rating by Jefferies given on Wednesday, October 11. On Monday, December 12 the stock rating was downgraded by Jefferies to “Underperform”. The firm has “Hold” rating given on Tuesday, April 4 by Jefferies. The rating was downgraded by Macquarie Research on Tuesday, November 29 to “Underperform”. The stock has “Hold” rating by Jefferies on Thursday, June 29. On Thursday, September 29 the stock rating was maintained by Jefferies with “Hold”. Jefferies maintained the shares of WOR in report on Wednesday, June 14 with “Hold” rating. The company was maintained on Thursday, March 29 by Jefferies. The firm has “Sell” rating by Jefferies given on Thursday, March 30. Jefferies maintained it with “Hold” rating and $47.0 target in Wednesday, September 6 report.

Investors sentiment decreased to 0.93 in Q4 2017. Its down 0.27, from 1.2 in 2017Q3. It fall, as 31 investors sold Worthington Industries, Inc. shares while 71 reduced holdings. 36 funds opened positions while 59 raised stakes. 31.16 million shares or 3.79% less from 32.39 million shares in 2017Q3 were reported. First Midwest Bank & Trust Tru Division holds 12,511 shares or 0.07% of its portfolio. Millennium Management Ltd Company holds 0% or 63,192 shares. Creative Planning reported 5,574 shares stake. Tcw Grp owns 94,164 shares for 0.03% of their portfolio. Summit Financial Strategies Incorporated owns 8,673 shares. Gateway Inv Advisers Ltd Limited Liability Company has 0.03% invested in Worthington Industries, Inc. (NYSE:WOR). Burney holds 112,430 shares or 0.28% of its portfolio. Tower Capital Limited (Trc) owns 0% invested in Worthington Industries, Inc. (NYSE:WOR) for 301 shares. Proshare Advsrs Ltd Co, a Maryland-based fund reported 13,877 shares. Strategic Global Advsrs Limited Liability Corporation has 0.14% invested in Worthington Industries, Inc. (NYSE:WOR). D E Shaw Com invested in 60,732 shares. The Texas-based Hbk Limited Partnership has invested 0% in Worthington Industries, Inc. (NYSE:WOR). Meeder Asset holds 266 shares. Amalgamated Bank & Trust has 0.01% invested in Worthington Industries, Inc. (NYSE:WOR). Hsbc Holdings Public Limited Liability holds 0% or 9,931 shares.

Worthington Industries, Inc. (NYSE:WOR) Institutional Positions Chart